Anti-PD-1/PD-L1 antibodies have shown promise as checkpoint inhibitors, with overall low response rates, and adverse events have been noted, underscoring the need for a better understanding of the PD-1-mediated immunosuppression of cancer [29]. The gene discussed is PDCD1; the disease is cancer.